Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature

Stefanie Slot*, Reinier A. P. Raymakers, Nicolaas Schaap, Lambert F. R. Span, Harry R. Koene, Sabina Kersting, Peter A. W. te Boekhorst, Matthijs Westerman, Harry C. Schouten, Sonja Zweegman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)624-634
Number of pages11
JournalClinical Lymphoma Myeloma & Leukemia
Volume19
Issue number10
DOIs
Publication statusPublished - Oct 2019

Keywords

  • Dosing
  • JAK2 inhibitor
  • Platelet count
  • Safety
  • Treatment
  • POLYCYTHEMIA-VERA
  • OPEN-LABEL
  • EFFICACY
  • MULTICENTER
  • SAFETY
  • CRITERIA
  • THERAPY

Cite this